Belantamab mafodotin

Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.[1][2][3][4]

Belantamab mafodotin
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetB-cell maturation antigen (BCMA) (CD269)
Clinical data
Trade namesBlenrep
Other namesbelantamab mafodotin-blmf, GSK2857916
AHFS/Drugs.comBlenrep
License data
Routes of
administration		Intravenous infusion
Drug classAntineoplastic
ATC code
  • None
Legal status
Legal status
Identifiers
UNII
KEGG
Chemical and physical data
FormulaC6484H10008N1728O2030S44. (C49H66N6O11)4

The most common adverse reactions include keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.[1][2]

Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF).[4] The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity.[4]

Belantamab mafodotin was approved for medical use in the United States in August 2020.[2][3] On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Blenrep.[4]

Medical uses

Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.[1][2][4]

Adverse effects

The prescribing information includes a boxed warning stating belantamab mafodotin causes changes in the corneal epithelium resulting in alterations in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.[2][1]

Because of the risks of ocular toxicity, belantamab mafodotin is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the BLENREP REMS.[2]

History

Belantamab mafodotin was evaluated in DREAMM-2 (NCT 03525678), an open-label, multicenter trial.[2] Participants received either belantamab mafodotin, 2.5 mg/kg or 3.4 mg/kg intravenously, once every three weeks until disease progression or unacceptable toxicity.[2]

Efficacy was based on overall response rate (ORR) and response duration, as evaluated by an independent review committee using the International Myeloma Working Group uniform response criteria.[2] The ORR was 31% (97.5% CI: 21%, 43%). Seventy-three percent of responders had response durations ≥6 months.[2] These results were observed in participants receiving the recommended dose of 2.5 mg/kg.[2]

The U.S. Food and Drug Administration (FDA) granted the application for belantamab mafodotin priority review, orphan drug designation, and breakthrough therapy designation.[2]

Society and culture

Belantamab mafodotin was approved for medical use in the United States in August 2020.[2][3]

Names

Belantamab mafodotin is the international nonproprietary name (INN).[5]

gollark: Hopefully the new version of NuclearCraft will make fusion less utterly disappointing.
gollark: I mean that there's been increased RAM use generally, not necessarily 1.13.
gollark: Also increased RAM use.
gollark: Huh. That would make my latest reactor work better.
gollark: The copper coolers have to touch two glowstone *anyway*, do they not?

References
  1. "Blenrep- belantamab injection, powder, lyophilized, for solution". DailyMed. 5 August 2020. Retrieved 11 August 2020.
  2. "FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma". U.S. Food and Drug Administration (FDA). 5 August 2020. Retrieved 6 August 2020. This article incorporates text from this source, which is in the public domain.
  3. "FDA Approves GSK's BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma" (Press release). GlaxoSmithKline. 6 August 2020. Retrieved 6 August 2020 – via Business Wire.
  4. "Blenrep: Pending EC decision". European Medicines Agency (EMA). 23 July 2020. Retrieved 6 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3): 431–2. hdl:10665/330907. License: CC BY-NC-SA 3.0 IGO.

Further reading
  • "Belantamab mafodotin". Drug Information Portal. U.S. National Library of Medicine.
  • "Belantamab mafodotin". NCI Drug Dictionary. National Cancer Institute.
  • Clinical trial number NCT03525678 for "A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.